Edwards Lifesciences Corporation reported a strong financial performance for the second quarter ending June 30, 2025, with sales increasing by 11.9% to $1.53 billion. The company's earnings per share $(EPS)$ for the quarter stood at $0.572, with an adjusted EPS of $0.67. Transcatheter Aortic Valve Replacement (TAVR) sales rose by 8.9%, contributing significantly to the overall growth. The Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $134.5 million, driven by the PASCAL and EVOQUE platforms. Edwards Lifesciences has increased its full-year total company sales growth guidance to 9% to 10%, projecting sales between $5.9 billion and $6.1 billion. The company has also adjusted its underlying growth rate guidance for TAVR to 6% to 7%, with anticipated sales ranging from $4.3 billion to $4.5 billion. For the third quarter, the company estimates total sales to be between $1.46 billion and $1.54 billion, with adjusted EPS projected to be between $0.54 and $0.60. Research and development expenses were $276 million in the quarter, representing 18.0% of sales, reflecting a strategic focus on expanding the structural heart portfolio. Operating profit margin for the second quarter was 26.8%, or 28.2% adjusted, benefiting from strong sales and deferred spending. The company ended the quarter with approximately $3 billion in cash and cash equivalents, and total debt of around $600 million. CEO Bernard Zovighian highlighted the company's balanced portfolio and leadership in aortic, mitral, and tricuspid therapies as key factors positioning Edwards Lifesciences for future growth.